Cerenome, Inc. (CNSY)
NASDAQ: CNSY · Real-Time Price · USD
0.6301
-0.0723 (-10.29%)
At close: Nov 20, 2026, 4:00 PM EST
0.6300
-0.0001 (-0.02%)
After-hours: Nov 20, 2026, 7:57 PM EST
Cerenome Employees
Cerenome had 28 employees as of December 31, 2025. The number of employees increased by 7 or 33.33% compared to the previous year. That makes Cerenome the 37,272nd largest employer in the world and 5,191st in the United States.
Employees
28
Change (1Y)
7
Growth (1Y)
33.33%
Revenue / Employee
$126,000
Profits / Employee
-$1,082,929
Market Cap
4.78M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 28 | 7 | 33.33% |
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Evogene | 52 |
| SeaStar Medical Holding | 18 |
| FibroBiologics | 15 |
| Soligenix | 14 |
| Kiora Pharmaceuticals | 13 |
| Processa Pharmaceuticals | 12 |
| CNS Pharmaceuticals | 8 |
| Can-Fite BioPharma | 5 |
CNSY News
- 4 days ago - Cerenome price target raised to $7 from $1 at H.C. Wainwright - TheFly
- 6 days ago - Cerenome Earnings Call Transcript: Q3 2026 - Transcripts
- 6 days ago - Cerenome Earnings release: Q3 2026 - Filings
- 6 days ago - Cerenome Quarterly report: Q3 2026 - Filings
- 6 days ago - Cerenome announces interim data from ReSPECT-LM study of Reyobiq - TheFly
- 6 days ago - Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting - GlobeNewsWire
- 8 days ago - Cerenome reports Q3 EPS ($1.14), consensus ($1.03) - TheFly
- 8 days ago - Cerenome Reports Third Quarter 2026 Financial Results and Business Highlights Featuring REYOBIQ ReSPECT- LM Data and CNSide Commercial and Reimbursement Progress - GlobeNewsWire